Heung Sik Kim

Heung Sik Kim

Auto-generated profile, based on publicly available information

Heung Sik Kim

Department of Pediatrics, Keimyung University Daegu Dongsan Hospital, Daegu, Korea

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
EPEun Sil Park
Eun Sil Park
KSKi Woong Sung
Ki Woong Sung
HBHee Jo Baek
Hee Jo Baek
KPKyung Duk Park
Kyung Duk Park
HPHyeon Jin Park
Hyeon Jin Park
HKHeung Sik Kim
Heung Sik Kim
Park ES, et al. J Korean Med Sci. 2012 Feb;27(2):135-140. http://dx.doi.org/10.3346/jkms.2012.27.2.135

31 March 2019 in Annals of Pediatric Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
SKSeok Jin Kang
Seok Jin Kang
RLRosie Lee
Rosie Lee
HKHeung Sik Kim
Heung Sik Kim
Idiopathic infantile hypercalcemia is characterized by hypercalcemia, dehydration, vomiting, and failure to thrive, and it is due to mutations in 24-hydroxylase (CYP24A1). Recently, mutations in sodium-phosphate cotransporter (SLC34A1) expressed in the kidney were discovered as an additional cause of idiopathic infantile hypercalcemia. This report describes a female infant admitted for evaluation of nephrocalcinosis. She presented with hypercalcemia, hypercalciuria, low intact parathyroid hormone level, and high 1,25-dihydroxyvitamin D3 level. Exome sequencing identified novel compound heterozygous mutations in SLC34A1 (c.1337G>A, c.1483C>T). The patient was treated with fluids for hydration, furosemide, a corticosteroid, and restriction of calcium/vitamin D intake. At the age of 7 months, the patient's calcium level was within the normal range, and hypercalciuria waxed and waned. Renal echogenicity improved on the follow-up ultrasonogram, and developmental delay was not noted. In cases of hypercalcemia with subsequent hypercalciuria, DNA analysis for SLC34A1 gene mutations and CYP24A1 gene mutations should be performed. Further studies are required to obtain long-term data on hypercalciuria and nephrocalcinosis.

31 July 2021 in Journal of Yeungnam Medical Science
Verified
Journal Article
Open access
PDF file
AKAbraham Kwak
Abraham Kwak
NJNani Jung
Nani Jung
YSYe Jee Shim
Ye Jee Shim
HKHeung Sik Kim
Heung Sik Kim
HLHyun Ji Lim
Hyun Ji Lim
YDYoung Rok Do
Young Rok Do
Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe, life-threatening inflammatory condition if untreated. We aimed to investigate the etiologies, outcomes, and risk factors for death in children and adults with HLH. The medical records of patients who met the HLH criteria of two regional university hospitals in Korea between January 2001 and December 2019 were retrospectively investigated. Sixty patients with HLH (35 children and 25 adults) were included. The median age at diagnosis was 7.0 years (range, 0.1-83 years), and the median follow-up duration was 8.5 months (range, 0-204 months). Four patients had primary HLH, 48 patients had secondary HLH (20 infection-associated, 18 neoplasm-associated, and 10 autoimmune-associated HLH), and eight patients had HLH of unknown cause. Infection was the most common cause in children (14/35, 40.0%), whereas neoplasia was the most common cause in adults (13/25, 52.0%). Twenty-eight patients were treated with HLH-2004/94 immunochemotherapy. The 5-year overall survival (OS) rate for all HLH patients was 59.9%. The 5-year OS rates for patients with primary, infection-associated, neoplasm-associated, autoimmune-associated, and unknown cause HLH were 25.0%, 85.0%, 26.7%, 87.5%, and 62.5%, respectively. Using multivariate analysis, neoplasm-induced HLH (p=0.001) and a platelet count <50×109/L (p=0.008) were identified as independent risk factors for poor prognosis in patients with HLH. Infection was the most common cause of HLH in children, while it was neoplasia in adults. The 5-year OS rate for all HLH patients was 59.9%. HLH caused by an underlying neoplasm or a low platelet count at the time of diagnosis were risk factors for poor prognosis.

15 December 2018 in Korean Journal of Pediatrics
Verified
Journal Article
Open access
ECEun Mi Choi
Eun Mi Choi
DLDong Hyun Lee
Dong Hyun Lee
SKSeok Jin Kang
Seok Jin Kang
YSYe Jee Shim
Ye Jee Shim
HKHeung Sik Kim
Heung Sik Kim
JJJa-Hyun Jang
Ja-Hyun Jang
Floating-Harbor syndrome is a rare autosomal dominant genetic disorder associated with SRCAP mutation. To date, approximately 50 cases of Floating-Harbor syndrome have been reported, but none have been reported in Korea yet. Floating-Harbor syndrome is characterized by delayed bony maturation, unique facial features, and language impairment. Here, we present a 6-year-old boy with a triangular face, deep-set protruding eyes, low-set ears, wide nose with narrow nasal bridge, short philtrum, long thin lips, clinodactyly, and developmental delay that was transferred to our pediatric clinic for genetic evaluation. He showed progressive delay in the area of language and cognition-adaption as he grew. He had previously undergone chromosomal analysis at another hospital due to his language delay, but his karyotype was normal. We performed targeted exome sequencing, considering several syndromes with similar phenotypes. Library preparation was performed with the TruSight One sequencing panel, which enriches the sample for about 4,800 genes of clinical relevance. Massively parallel sequencing was conducted with NextSeq. An identified variant was confirmed by Sanger sequencing of the patient and his parents. Finally, the patient was confirmed as the first Korean case of Floating-Harbor syndrome with a novel SRCAP (Snf2 related CREBBP activator protein) mutation (c.7732dupT, p.Ser2578Phefs*6), resulting in early termination of the protein; it was not found in either of his healthy parents or a control population. To our knowledge, this is the first study to describe a boy with Floating-Harbor syndrome with a novel SRCAP mutation diagnosed by targeted exome sequencing in Korea.

5 February 2021 in Children
Verified
Journal Article
Open access
PDF file
JLJae Min Lee
Jae Min Lee
EYEu Jeen Yang
Eu Jeen Yang
KPKyung Mi Park
Kyung Mi Park
YLYoung-Ho Lee
Young-Ho Lee
HCHeewon Chueh
Heewon Chueh
YLYoung Tak Lim
Young Tak Lim
Acute myeloid leukemia (AML) is the second most common pediatric leukemia, with a survival rate of 70%. In this retrospective study, we evaluated the treatment outcomes of pediatric AML among 144 patients diagnosed between 2000 and 2013. After induction, 80.6% of patients achieved complete remission (CR). The 5-year overall survival (OS) and event-free survival (EFS) rates were 58.8 ± 4.2% and 49.8 ± 4.2%, respectively. Based on the response to induction therapy, the 5-year OS was 66.9 ± 5.7% in patients with CR (p < 0.001). Ninety-nine patients with CR after induction therapy were examined, and their 5-year OS and EFS were 66.4 ± 4.9% and 56.3 ± 5.1%, respectively. The 5-year OS rates according to treatment were 59.9 ± 7.4% in the chemotherapy group and 72.3 ± 6.3% in the hematopoietic stem cell transplantation (HSCT) group (p = 0.089). The EFS was 50.1 ± 7.4% in the chemotherapy group and 61.7 ± 6.9% in the HSCT group (p = 0.098). OS and EFS according to cytogenetics were insignificant. Our findings confirmed that the response to induction treatment was important for survival and HSCT had no significant survival benefits compared with those of chemotherapy. Moreover, many early induction deaths under the age of 2 years were observed.

1 January 2006 in Korean Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
SPSun Mi Park
Sun Mi Park
BCByung Kyu Choe
Byung Kyu Choe
YKYeo Hyang Kim
Yeo Hyang Kim
HKHeung Sik Kim
Heung Sik Kim
TKTae Chan Kwon
Tae Chan Kwon
HLHee Jung Lee
Hee Jung Lee
Park SM, et al. Korean J Pediatr. 2006 Jun;49(6):691-695. http://dx.doi.org/10.3345/kjp.2006.49.6.691